BRITSpA at five

Andrew Keat; Alexander N Bennett; Karl Gaffney; Gareth T Jones; Jane Martindale; Raj Sengupta; Stefan Siebert; Helena Marzo-Ortega

doi:10.1093/rheumatology/kez523

BRITSpA at five

Andrew Keat, Alexander N Bennett, Karl Gaffney, Gareth T Jones, Jane Martindale, Raj Sengupta, Stefan Siebert, Helena Marzo-Ortega^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Editorial

Abstract

It may seem that spondyloarthritis (SpA) has come of age, with new pathogenetic insights, valuable animal models and effective biologic therapies that have led to significant improvements in affected individuals. However, for all patients to receive the best care and for every research opportunity to be taken, clinicians and scientists in each country need to collaborate locally as well as internationally to ensure that innovations lead to the best possible care delivery within the context of each nation’s health services structure.

Original language	English
Pages (from-to)	699-701
Number of pages	3
Journal	Rheumatology
Volume	59
Issue number	4
Early online date	9 Nov 2019
DOIs	https://doi.org/10.1093/rheumatology/kez523
Publication status	Published - 1 Apr 2020

Access to Document

10.1093/rheumatology/kez523Licence: Unspecified

Cite this

@article{6ee47aba071740fe82a0c95e8dae0098,

title = "BRITSpA at five",

abstract = "It may seem that spondyloarthritis (SpA) has come of age, with new pathogenetic insights, valuable animal models and effective biologic therapies that have led to significant improvements in affected individuals. However, for all patients to receive the best care and for every research opportunity to be taken, clinicians and scientists in each country need to collaborate locally as well as internationally to ensure that innovations lead to the best possible care delivery within the context of each nation{\textquoteright}s health services structure.",

author = "Andrew Keat and Bennett, {Alexander N} and Karl Gaffney and Jones, {Gareth T} and Jane Martindale and Raj Sengupta and Stefan Siebert and Helena Marzo-Ortega",

note = "The authors would like to thank Dr Mohammad Derakhshan, BRITSpA Research Fellow (2016–2019) and Karly Graham, administrator. H.M.O. is supported by the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health. Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.",

year = "2020",

month = apr,

day = "1",

doi = "10.1093/rheumatology/kez523",

language = "English",

volume = "59",

pages = "699--701",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "OXFORD UNIV PRESS INC",

number = "4",

}

TY - JOUR

T1 - BRITSpA at five

AU - Keat, Andrew

AU - Bennett, Alexander N

AU - Gaffney, Karl

AU - Jones, Gareth T

AU - Martindale, Jane

AU - Sengupta, Raj

AU - Siebert, Stefan

AU - Marzo-Ortega, Helena

N1 - The authors would like to thank Dr Mohammad Derakhshan, BRITSpA Research Fellow (2016–2019) and Karly Graham, administrator. H.M.O. is supported by the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health. Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.

PY - 2020/4/1

Y1 - 2020/4/1

N2 - It may seem that spondyloarthritis (SpA) has come of age, with new pathogenetic insights, valuable animal models and effective biologic therapies that have led to significant improvements in affected individuals. However, for all patients to receive the best care and for every research opportunity to be taken, clinicians and scientists in each country need to collaborate locally as well as internationally to ensure that innovations lead to the best possible care delivery within the context of each nation’s health services structure.

AB - It may seem that spondyloarthritis (SpA) has come of age, with new pathogenetic insights, valuable animal models and effective biologic therapies that have led to significant improvements in affected individuals. However, for all patients to receive the best care and for every research opportunity to be taken, clinicians and scientists in each country need to collaborate locally as well as internationally to ensure that innovations lead to the best possible care delivery within the context of each nation’s health services structure.

UR - https://doi.org/10.1093/rheumatology/kez523

UR - http://www.scopus.com/inward/record.url?scp=85082542197&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kez523

DO - 10.1093/rheumatology/kez523

M3 - Editorial

C2 - 31710687

VL - 59

SP - 699

EP - 701

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 4

ER -

BRITSpA at five

Abstract

Access to Document

Other files and links

Fingerprint

Cite this